Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance. [electronic resource]
Producer: 20140509Description: 53-64 p. digitalISSN:- 1365-2141
- Antibodies, Monoclonal, Humanized -- pharmacology
- Antibodies, Monoclonal, Murine-Derived -- pharmacology
- Antineoplastic Agents -- pharmacology
- Apoptosis -- drug effects
- B-Lymphocytes -- drug effects
- Bone Marrow Cells -- physiology
- Cell Adhesion -- drug effects
- Coculture Techniques
- Drug Resistance, Neoplasm -- drug effects
- Humans
- Integrin alpha4beta1 -- antagonists & inhibitors
- Lymphoma, B-Cell -- drug therapy
- Natalizumab
- Rituximab
- Stromal Cells -- physiology
- Tumor Cells, Cultured
- Tumor Microenvironment -- drug effects
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.